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Abstract
Aims: New strategies to overcome complications of cardiovascular diseases are needed. Since it has been demonstrated
that atherosclerosis is an inflammatory disease, modulation of the immune system may be a promising approach.
Previously, it was suggested that antibodies may confer protective effects on the development of atherosclerosis. In this
study, we hypothesised that passive immunization with anti-oxLDL IgM antibodies specific for hypochlorite (HOCl) may be
athero-protective in mice.
Methods and Results: Monoclonal mouse IgM antibodies were produced and the antibody with specificity for hypochlorite-
oxLDL (HOCl-oxLDL) (Moab A7S8) was selected. VH sequence determination revealed that Moab A7S8 is a natural IgM
antibody. Atherosclerosis in LDLr2/2 mice was induced by a perivascular collar placement around the right carotid artery in
combination with feeding a high-fat diet. Subsequently, the mice were treated every six days with 500 mg Moab A7S8, non-
relevant IgM or with PBS and the carotid arteries and aortic roots were studied for atherosclerosis. Passive immunization
with this Moab A7S8 resulted in a significant reduced plaque volume formation in LDLr2/2 mice when compared with PBS
treatment (P = 0.002 and P = 0.035). Cholesterol levels decreased by 20% when mice were treated with Moab A7S8
compared to PBS. Furthermore, anti-oxLDL specific IgM and IgG antibody production increased significantly in the Moab
A7S8 treated mice in comparison with PBS treated mice.
Conclusion: Our data show that passive immunization with a natural IgM antibody, directed to HOCl-oxLDL, can reduce
atherosclerotic plaque development. We postulate that specific antibody therapy may be developed for use in human
cardiovascular diseases.
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Introduction
Atherosclerosis is the most important underlying cause of
cardiovascular diseases and is a major contributor of morbidity
and mortality in the western society. In large randomized clinical
trials complications such as myocardial infarction and stroke, are
reduced by less than 50% with current therapy. Therefore,
development of novel therapeutic strategies is highly needed to
complement or replace current treatments [1]. Both the cellular
and humoral immune responses has been increasingly recognized
as essential in atherogenesis [2].
Immune-modulation therapy via a passive immunization
strategy aims to exploit the athero-protective aspects of the
immune system to modulate the development of atherosclerosis
[3,4]. It was demonstrated in a vein graft atherosclerosis model
that passive immunization with T15 natural IgM antibodies could
reduce plaque development by 25% [5]. This suggests a potential
role for IgM antibodies in passive immunization strategies. T15
IgM antibodies are considered to be part of the innate immune
response which are of natural origin. These antibodies are secreted
by distinct sets of innate-like B cells, B21 cells and marginal zone
B cells, which arise early in development and become the source of
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‘‘natural immune memory’’. Due to their interactions with a
variety of self-determinants, natural antibodies have previously
been postulated to be important for the maintenance of host
homeostasis [6,7]. Oxidation derived epitopes on apoptotic cells
and on LDL (oxLDL) are recognized by the phosphorylcholine
(PC) – specific encoded B21 cell natural T15 antibody [6]. In vitro,
IgM autoantibodies to oxLDL block the binding and degradation
of oxLDL by macrophages [8]. Increased levels of natural IgM
T15 antibodies with specificity for the phosphorylcholine epitope
provide a protective effect in mouse atherosclerosis as shown by a
reduction of atherosclerotic plaque formation [9,10]. Moreover,
high levels of immunoglobulin M type of autoantibodies against
phosphorylcholine were found to be protective against human
atherosclerosis [11–13], the latter was also found to be a
prognostic factor in acute coronary syndromes [14].
OxLDL plays a pivotal role throughout development of
atherosclerosis. Modification of LDL into its oxidized form is
caused by several different mechanisms. One clinically relevant
pathway is via myeloperoxidase (MPO) and its oxidant product
hypochlorite (HOCl) [15,16]. Active MPO can be demonstrated
in extracts from human atherosclerotic arteries [17], circulating
MPO levels independently predict the risk to develop events of
cardiovascular diseases [18,19] and 2463 MPO polymorphism
predicts the risk for cardiovascular events [20]. In mice and
humans, increased titers of autoantibodies against HOCl-oxLDL
have been reported during atherogenesis [4,21–23]. Recently, we
demonstrated presence of neutrophils with co-localized MPO in
mouse atherosclerotic plaques [24]. Furthermore, increased levels
of circulating MPO were observed in atherosclerosis prone mice
upon high-fat feeding [24].
We hypothesised that atherosclerotic plaque development can
be reduced with passive immunization of IgM antibodies specific
for HOCl-oxLDL. To test this hypothesis, we selected a
monoclonal antibody that bound to hypochlorite-oxLDL and




The investigation conforms to the Guide for the Care and Use
of Laboratory Animals published by the directive of the European
Parliament (Directive 2011/63/EU). Approval was granted by the
ethics review board of Maastricht University (reference number:
2008–111) and carried out in compliance with the Dutch
government.
Immunization and Culture of Hybridoma Cell Line
Balb/C mice were immunized with hypochlorite-modified
oxLDL [21]. Mice received an intraperitoneal dose of 50 mg of
oxLDL in 100 ml sterile-filtered PBS and an equal volume of
Complete Freund`s Adjuvant on day 0, followed on day 21 and 35
by booster injections of 50 mg oxLDL in Incomplete Freund`s
Adjuvant. Five days before sacrifice, 50 mg of oxLDL was
administered intravenously. At day 48, mice were sacrificed and
spleens were harvested. A single cell suspension was prepared and
fused with the HAT-sensitive cell line SP2O. Anti-oxLDL IgM
producing clones were selected by enzyme-linked immunosorbent
assay (ELISA) as described before [22].
Generation and Purification of IgM Antibodies
Antibody-containing medium was generated by culturing the
hydridoma cell line in IMDM containing 1% FCS. To IgM-
containing medium, 0.75 M of amoniumsulfate was added and the
medium was loaded on a thiophilic agarose resin. The column was
eluded using a 50 mM Tris-HCl buffer at pH 8.9. Protein
concentration was determined as absorption at A280. Purified
IgM antibodies were dialysed against PBS and subsequently
filtered by a 0.2 mM filter and stored at 280uC.
Characterization of Anti-oxLDL IgM Antibody
Western blotting. Purified monoclonal IgM antibody recog-
nizing HOCl-modified LDL was obtained as described above. The
antibody preparation was dissolved in non-reducing sample buffer
and analyzed by SDS- Poly-Acrylamide-Gel Electrophoresis (SDS-
PAGE), using a modification of the method described by Laemmli
[25]. Ten mg protein were run on a 2–10% gradient gel for four
hours at maximal 400 volt, and proteins were transferred to
nitrocellulose membrane (Schleicher Schuell, Keene, NH) during
one hour at 70 V. Following blocking with NaCl/Tris buffer
containing 1% bovine serum albumin (BSA; Merck, Darmstadt,
Germany), blots were incubated with anti-IgM antibody coupled
to alkaline phosphatise; staining was visualized using an AP vector
kit (Vectot Laboratories, Burlingame, CA) according to the
manufacturer’s instructions.
Mouse monoclonal antibody isotype determination. The
one-step mouse monoclonal antibody determination (Mouse mAb
isotyping kit, HBT, Uden, The Netherlands) procedure involves
the capture of the mouse immunoglobulins by subclass specific rat
anti-mouse monoclonal antibodies which are immobilized on the
test strip.
Reactivity of monoclonal IgM with LDL and
oxLDL. LDL was isolated according to Smook et al. [26]
Shortly, native LDL and hypochlorite oxidized LDL (HOCl) was
coated in a concentration of 100 mg/ml in PBS, in microtitre
plates (Nunc MaxiSorpTM, Nalgene Nunc, Rochester, NY)
overnight at 4uC. Wells were then washed five times with a buffer
containing 0.01 M Tris, 0.15 M NaCl and 0.05% Tween 20
(pH 8.0) followed by incubation with pure monoclonal IgM
antibody in different concentrations (100, 50, 25 10 and 1 mg/ml),
100 ml/well, in a buffer containing 0.1 M Tris, 0.3 M NaCl and
0.05% Tween 20 (pH 8.0) and incubated overnight at 4uC as
previously described [22]. A positive control was used on each
plate. The next day, plates were washed and incubated with
alkaline phosphatase conjugated goat F(ab9)2 anti-mouse IgM
(mchain)-specific conjugate (Jackson Immunoresearch Laborato-
ries, Inc., The Netherlands), diluted 1:2000 in incubation buffer
for 1 hour at 37uC. After washing, 100 ml of freshly made
substrate containing 1 mg/ml of nitrophenyl phosphate in di-
ethanolamine buffer at pH 9.8 was added to each well. Plates were
read at 405 nm.
Determination VH sequence of the monoclonal IgM
antibody. To determine the VH sequence of the IgM
monoclonal antibody, the heavy chain was cloned and sequenced
after amplification with universal VH gene specific 59 AGGTS-
MARCTGCAGSAGTCWGG 39 [27] and a primer for the
constant region of IgM 59 [28]. The sequence was compared with
germline VH genes by using the international ImMunoGeneTics
information system/2QUEry and Standardization (IMGT/V-
Quest) software program [29]. Following comparison with the
IMGT reference directory, IMGT/V-QUEST identifies the
variable (V), diversity (D) and Joining (J) germline alleles involved,
determines the N-junctional diversity, and calculates the percent-
age nucleotide mismatches, suggestive for somatic hypermutation.
Collar-induced atherosclerosis. Twelve-week-old male
LDLr2/2 mice (n = 18 per group), obtained from the Jackson
Laboratory, were operated after 2 weeks of high fat diet (0.25%
cholesterol, 16% fat) to introduce a 2 mm long non-constrictive
Anti-HOCl-oxLDL Antibody Reduces Atherosclerosis
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silastic tube around both carotid arteries, as described before [30].
Mice were anesthetized by 3 - 4% isoflurane and maintained by
1.5–2.5%. Pain relief was accomplished by a subcutaneous
injection of buprenorphine 0.1 mg/kg preoperative and at the
end of the day. During the 6 post-operative weeks, the high-fat diet
was continued and the mice were treated every six days by an
intraperitoneal injection with 500 mg Moab A7S8, starting from
day two after collar placement. In addition, two control groups of
mice were treated every six days with 500 mg PBS or a non-
relevant IgM monoclonal antibody directed to human anti-EGP2/
anti-epCAM (MOC153, a generous gift from prof. dr. L.F.M.H.
(Lou) de Leij, University Medical Center Groningen, Groningen,
The Netherlands). A final intraperitoneal injection was given
24 hour before sacrifice. In total 8 injections were given (see
figure 1A,B for experimental design). The mice were sacrificed by
carbon dioxide (gruadual fill) and were exsanguinated. Upon
sacrifice the right carotid artery was isolated and embedded in
paraffin. Sections of 5 mm were made and from every 100 mm,
sections were stained with haematoxilin/eosin for lesion area
analysis. After sacrifice, the heart and aorta were taken out,
embedded in OCT (Sakura Finetek, Zoeterwoude, The Nether-
lands), and frozen on dry ice. The hearts were cut perpendicular to
the heart axis just below the atrial tips. Sections of 7 mm were cut
out of the heart in the area where the atrioventricular valves were
visible. For lesion area measurements, four toluidin-stained
sections, with an interval of 42 mm, were analyzed using Adobe
Photoshop software, as described previously [31,32].
Antibody measurement. To determine anti-oxLDL anti-
body titers, ELISAs were performed as described below. Blood
samples were taken: before introduction HFD (T =22), one day
before collar placement (T = 0), one week after collar placement
(T = 1; after 16 intervention with PBS or Moab A7S8), 3 weeks
after collar placement (T = 3; after 56 intervention with PBS or
Moab A7S8) and on day of sacrifice (T = 6; after 86 intervention
with PBS or Moab A7S8).
Total IgM antibody. Total IgM and IgG levels were
measured in a chemiluminescent-based sandwich ELISA using
polyclonal goat anti-mouse IgM for capture and alkaline
phosphatase (AP)-labeled goat anti-mouse IgM (m-chain specific)
for detection. Sera were diluted 1:10.000 for total IgM.
MDA-LDL and copper-oxLDL antibody titers. Human
LDL was isolated and MDA-LDL and copper-oxidized LDL were
prepared as described [10]. Specific antibody titers were
determined by chemiluminescent enzyme immunoassays as
described [9,33]. Briefly, sera were diluted 1:100 and antibody
Figure 1. Schematic representation of the collar model and the experimental design. A. Atherosclerotic lesions develop caudal to the
collar, cross-sections were made of the common right carotid artery in a caudal direction from the collar and collected in a parallel series of slides, B.
Time schedule of the experiment to study the effect of passive immunization using Moab A7S8 or PBS on atherosclerotic plaque development.
doi:10.1371/journal.pone.0068039.g001
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binding to the indicated antigens was measured using the following
secondary antibodies: alkaline phosphatase (AP)-labeled goat anti-
mouse IgM (m-chain specific) and IgG (c-chain specific) (Sigma).
IgM - apoB immune complexes. ApoB-100 particles were
captured on microtiter wells using LF3, a monoclonal antibody
specific for murine apoB-100 which was coated on microtiter wells
at 5 mg/ml in PBS. After washing and blocking steps, plasmas
(1:100 in BSA-PBS) were incubated in wells for 1 hour at room
temperature and after further washing, bound IgM or IgG was
detected using AP-conjugated goat anti-mouse IgM or anti-IgG by
chemiluminescent ELISA. For detection of T15/EO6 antibodies
bound to the captured apoB-containing particles, biotinylated
AB1–2 was used, followed by incubation with AP-labeled
NeutrAvidin and LumiPhos 530. In parallel wells, the relative
amount of apoB captured in each sample was determined using
biotinylated LF5, another monoclonal antibody specific for mouse
apoB-100, followed by incubation with AP-labeled NeutrAvidin
and LumiPhos 530. Because LF5 binds to only one epitope of
apoB-100, the amount of each antibody used in this assay bound
to the captured LDL was then normalized for the amount of
captured apoB, and expressed as a ratio of antibody counts (RLU/
100 ms) to apoB-100 counts (RLU/100 ms) [9].
Hypochlorite-oxLDL antibody titers. LDL was isolated
from a plasma pool of healthy human subjects. Shortly, HOCl
modification was performed by coating 100 ml of native LDL,
diluted to 100 mg/ml in PBS, in microtitre plates (Nunc
MaxiSorpTM, Nalgene Nunc, Rochester, NY, USA) overnight at
4uC. After washing three times with PBS, half of each plate was
incubated for 2 hours at 4uC in 36 mM sodium HOCl (Sigma, St
Louis, MO, USA) in PBS; the other half of the plate was incubated
in PBS. Incubation was followed by a washing with PBS to stop
the reaction, and plates were stored in PBS at 4uC for a maximum
of 2 h before starting the enzyme-linked immunosorbent assay
(ELISA). Wells were then washed five times with a buffer
containing 0.01 M Tris, 0.15 M NaCl and 0?05% Tween 20
(pH 8.0) followed by incubation in duplo with mouse plasma in a
1:50 dilution, 100 ml/well, in a buffer containing 0.1 M Tris,
0.3 M NaCl and 0.05% Tween 20 (pH 8.0) and incubated
overnight at 4uC. A positive control was used on each plate to test
for intra-assay variation. The next day, plates were washed and
incubated with alkaline phosphatase conjugated goat F(ab9)2 anti-
mouse IgM (mchain)-specific conjugate (Jackson Immunoresearch
Laboratories, Inc., The Netherlands), diluted 1:2000 in incubation
buffer for 1 h at 37uC. After washing, 100 ml of freshly made
substrate containing 1 mg/ml of nitrophenyl phosphate in di-
ethanolamine buffer at pH 9.8 was added to each well. Plates were
read at 405 nm. Results are expressed as mean absorbance values
(405 nm) from duplicate determinations and were calculated by
subtracting binding to native LDL from binding to oxLDL.
EO6/T15 clonotypic antibody titers. For the detection of
the natural IgM T15 clonotypic antibodies (e.g., EO6) in the
plasma of mice, a chemiluminescent-based double antibody
capture assay was used [10]. In this assay, a monoclonal anti-
T15–idiotypic antibody AB1–2, a mouse IgG1, specific for both
the canonical T15 VH and the T15 VL regions was used as
capturing antibody. For the assay, 2 mg/ml of AB1–2 in PBS was
coated on microtitre plates overnight at 4uC. After washing and
blocking steps, 50 ml of murine plasma diluted by 1:100 in BSA-
PBS was incubated overnight at 4uC. After further washing,
captured T15-clonotypic antibodies were detected using an AP-
conjugated goat-anti-mouse IgM (Sigma, St Louis, MO, USA)
diluted in BSA-TBS, and a 50% aqueous solution of LumiPhos
530.
Collagen content. Picro-Sirius red staining was analyzed to
determine collagen content within lesions in LDLr2/2 mice.
Collagen positive area was determined from the largest athero-
sclerotic plaque of each mouse and analysed by expressing the
stained surface area as a percentage of the total area of the plaque.
Plasma cholesterol. lasma samples for cholesterol determi-
nation were taken before start of the HFD, before collar placement
and when mice were sacrificed. All plasma samples were taken
after overnight fasting. Plasma cholesterol levels were measured
with a commercially available kit (Sigma) following manufacturer’s
instructions.
Figure 2. IgM Monoclonal antibody (Moab A7S8). A. Reactivity to
native, HOCL-oxLDL and MDA-oxLDL. Measured by ELISA, OD 405 at
different concentrations (100, 50, 25, 10 and 1 mg/ml IgM concentra-
tion). B. Sequence IgM hybridoma. The sequence of Moab A7S8 was
compared with germline VH genes by using the international
ImMunoGeneTics information system/2QUEry and Standardization
(IMGT/V-Quest). Moab A7S8 is composed of IgHV1–78*01, IGHJ3*01
and IGHD1-1*02 alleles, with 100% identity and no gaps. Except for the
N-addition, the alleles are in frame germline sequences.
doi:10.1371/journal.pone.0068039.g002
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Figure 3. Atherosclerotic plaque volume at the collar and aortic root. A. Representative lesions of PBS and Moab A7S8 treated mice of collar-
induce atherosclerosis in LDLr2/2 mice. Scale bar, 100mm (haematoxylin-eosin). B. Percentage mice with atherosclerotic plaque formation after
certain distances from collar. Closed bars: PBS treated mice. Grey bars: control IgM treated mice. Open bars: Moab A7S8 treated mice. C.
Representative lesions in the aortic root of PBS and Moab A7S8 treated LDLr2/2 mice. Scale bar, 100 mm (toluidin blue). D. Atherosclerotic plaque
volume in the aortic root. Plaque volume, expressed in mm2. E. Collar-induced atherosclerotic plaque volume, measured at every 50 mm from collar,
in PBS (&), control IgM (#) and Moab A7S8 (%) treated mice. A dot represents the mean 6 SEM.
doi:10.1371/journal.pone.0068039.g003
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Statistical analysis. All statistical analyses were performed
using GraphPad Prism (GraphPad Software Inc., San Diego,
California, USA). Errors are shown as SEM and P,0.05 was
considered as significant. Plaque volume measurements at the
collar were done by a 2-way ANOVA. Differences between groups
were analysed using a 1-way ANOVA when several groups were
analysed; a two-tailed Student’s t-test or the Mann-Whitney U-test
was used when comparing two groups with parametric or non-
parametric data, respectively.
Results
Characteristics Monoclonal Antibody A7S8 (Moab A7S8)
To create an IgM monoclonal antibody to oxLDL, we
immunized mice with human oxLDL. With ELISA techniques,
we have selected and up scaled a monoclonal IgM antibody with
specificity for HOCl-oxLDL, designated Moab A7S8. This Moab
A7S8 was detected to be a pentameric IgM (k) with no further
degradation, which was shown by western blotting techniques by
which a protein at approximately 800 kb (data not shown) was
detected. The specificity of Moab A7S8 was shown using ELISA
in which Moab A7S8 reacted strongly with HOCl-oxLDL and
malonaldehyde (MDA)-oxLDL (Figure 2A). No reactivity in this
assay was observed with Cu-oxLDL, phosphorylcholine or native
LDL showing Moabs A7S8 specificity. The non-relevant control
IgM showed no reactivity with HOCl-oxLD, MDA-oxLDL, Cu-
oxLDL or native LDL (data not shown).
Moab A7S8 is composed of IgHV1–78*01, IGHJ3*01 and
IGHD1–1*02 alleles, with 100% identity and no gaps. Except for
N-addition, the alleles are in frame germline sequences, therefore
B cell clone A7S8 produces a prototypical natural IgM antibody
with an affinity for oxLDL (Figure 2B).
Treatment with the A7S8 Antibody Result in a Decrease
in Atherosclerotic Plaque Volume
To evaluate the effect of a passive immunization strategy using
our Moab A7S8 with specificity for HOCl-oxLDL on the
development of atherosclerosis, LDLr2/2 mice were 8 times
injected intraperitoneally with Moab A7S8, control-IgM or PBS.
At sacrifice, plaques were located in the proximal area to the collar
and in the aortic root. Atherosclerotic plaque formation in the
right carotid artery was analyzed using haematoxilin-eosin
staining. Treatment of anti-oxLDL natural IgM antibodies
resulted in a significant reduced plaque volume formation at the
collar (p = 0.002, figure 3A,B,E) in atherosclerotic mice. Mice
injected with PBS or control-IgM develop a plaque volume which
reaches to the 1150 mm distance from the collar. In contrast, mice
treated with anti-oxLDL IgM antibodies develop plaque content
to a distance of 750 mm from the collar (Figure 3B,E). At 750 mm
from the collar, only 14% of the Moab A7S8 treated mice show
any plaque development in the carotid artery, whereas 40% of the
PBS treated mice demonstrated plaque formation at that site
(Figure 3D,E). Beyond 750 mm distance from the collar, plaque
formation was virtually blocked by the treatment with Moab A7S8
as shown by the highly significant effects at these distances. At the
aortic root, the average plaque size measured in the mice treated
with PBS, control-IgM and Moab A7S8 was respectively 330 mM2
(SEM 25), 295 mM2 (SEM 28) and 263 mM2 (SEM 17)
(figure 3C,D). The reduction in plaque size after treatment with
Moab A7S8 was significant when compared to PBS treatment
(p = 0.0352), while non-significant compared to control-IgM
treatment (p = 0.3299).
As shown in Figure 4, there was no difference between mice
treated with PBS or treated with Moab A7S8 in total collagen
content of their plaques (PBS: 27% 613 and Moab A7S8:29%
618; P = 0.588). Total cholesterol levels and body weight were
measured at three different time points during the experiment.
During the experiment, PBS, C-IgM and Moab A7S8 treated
mice did not differ in body weight (weight in grams at sacrifice:
PBS: 2360.4, C-IgM: 2360.2, Moab A7S8:2360.2). Cholesterol
levels were the same at baseline (T =22) and before carotid collar
placement (T = 0). At sacrifice, however, mice treated with Moab
A7S8 showed a significant (P = 0.01) 20% lower plasma cholesterol
compared to mice injected with PBS (PBS: 4968 mM/l; Moab
A7S8:4168.5 mM/l, see figure 5). Compared to C-IgM treat-
ment, plasma cholesterol levels in the Moab A7S8-treated group
were also lower, although not statistically significant (C-IgM:
44610.5 mM/l).
Total IgM and anti-oxLDL IgM Antibody Levels
At T =22 and T = 1 (in weeks), no differences could be
observed in total IgM titers, HOCl-oxLDL and MDA-oxLDL
IgM levels in mice treated with PBS or Moab A7S8. However,
after 5 injections (T = 3) of Moab A7S8 antibodies a significant
increase in total IgM, HOCl-oxLDL and MDA-oxLDL IgM
antibodies could be observed compared to the PBS treated group.
The total IgM levels also increased after this point in time in the
PBS and C-IgM group, but to a lower extent compared to the
Figure 4. Collagen content in the atherosclerotic plaque.
Percentage positive collagen of the total plaque area. In PBS (&) and
Moab A7S8 (%) treated mice.
doi:10.1371/journal.pone.0068039.g004
Figure 5. Cholesterol levels. Serum cholesterol levels are expressed
as mM (6 SEM). Closed bars: PBS treated mice. Grey bars: control IgM
treated mice. Open bars: Moab A7S8 treated mice.
doi:10.1371/journal.pone.0068039.g005
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Figure 6. Total IgM and HOCl and MDA anti-oxLDL IgM titers. A. Total IgM titers, B. anti-HOCl oxLDL IgM titers and C. anti-MDA oxLDL IgM in
PBS treated mice (&), control IgM treated mice (o) and Moab A7S8 treated mice (%).
doi:10.1371/journal.pone.0068039.g006
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Moab A7S8 treated group. Further, it could be observed that the
difference between the A7S8 and the control groups were higher
for the HOCl-oxLDL and MDA-oxLDL IgM antibodies com-
pared to total IgM. Comparable but more pronounced differences
could be observed after 3 more injections (T = 6) (Figure 6).
Also, after 3 weeks and 6 weeks of Moab A7S8 treatment, Cu-
oxLDL IgM, T15 IgM antibodies and IgM-apoB Immune
complexes increased dramatically (Figure 7). These very specific
effects that occur beyond 3 weeks of treatments clearly show the
active biological consequences of the passive immunization
treatment with Moab A7S8.
Anti-oxLDL IgG Levels
At T =22, T = 0 and T = 1 (in weeks), no differences could be
observed in HOCl-oxLDL IgG, MDA-oxLDL IgG and Cu-
oxLDL IgG titers. However as also was demonstrated for the IgM
anti-oxLDL antibodies, in addition, also IgG titers against HOCl-
oxLDL and MDA-oxLDL significantly rose after 3 and 6 weeks of
Moab A7S8 treatment (Figure 8).
Discussion
This study demonstrates that passive immunization with Moab
A7S8 directed against HOCl-oxLDL results in decreased athero-
sclerosis development. By injecting Moab A7S8, we observed in
our collar model a significant decrease of plaque development
compared to PBS treatment. During lesion development, choles-
terol levels decreased and anti-oxLDL IgM and IgG titers
increased.
Several modifications of LDL into oxidized forms of LDL
(oxLDL) can occur during atherosclerosis development. Hypo-
chlorite (HOCl) is the product of the H2O2-catalyzed oxidation of
chloride by the enzyme myeloperoxidase (MPO). HOCl is highly
reactive and can result in the oxidation of the LDL particle [16].
Modification of LDL by HOCl is an important in vivo oxidation
pathway since MPO, released from plaque-infiltrating neutrophils
and monocytes, is abundantly present in atherosclerotic plaques
[17,24]. Importantly, several studies have furthermore implicated
a role for MPO in human cardiovascular diseases [18–20,34].
By VH sequencing, we could determine that our Moab A7S8 is
a natural antibody. With their ability to recognize self, altered self
and foreign antigens, natural antibodies comprise an important
first-line defense against invading pathogens, but are also
important for tissue homeostasis [6,7]. Recently, Chou et al.
[33] demonstrated that oxidation-specific epitopes constitute a
dominant target for natural antibodies. Approximately 30% of all
IgM-secreting clones produce natural antibodies that can bind to
oxidation-specific epitopes [33]. Inflammatory events, as in
atherosclerosis occurs, are associated with enhanced oxidative
stress, and different oxidation-specific antibodies are induced not
only during atherogenesis, but also in a variety of other
inflammatory settings [35,36]. Therefore, it was no surprise that
our Moab A7S8 IgM appeared to be part of these natural
antibodies recognizing oxidation-specific epitopes. Previously, it
has been shown that another natural antibody EO6/T15 is
athero-protective, in part through inhibiting the uptake of oxLDL
by macrophages [10]. Chou et al. [33] have shown that another
natural antibody, clone NA-17, has also the ability to inhibit the
uptake of MDA-oxLDL by macrophages in a similar manner as
the T15/EO6 antibody. This mechanism has also been demon-
strated in humans where anti-phosphorylcholine IgM could inhibit
the ex vivo uptake of modified LDL by macrophages [37].
Therefore, it is not unlikely that our Moab A7S8 confers also these
abilities to inhibit uptake of oxLDL by macrophages. Moab A7S8
differs from the EO6/T15 antibody in VH gene usage: Moab
A7S8 uses the IgHV1–78*01 VHgene that is a member of the
J558 (V1) VH gene family, whereas EO6/T15 uses the
S107.1 VH gene. Therefore, we postulate that our Moab A7S8
recognizes other epitope(s) than the EO6/T15 antibody, and
possibly could have other (stronger) effects on atherogenesis.
Epitope mapping of our Moab A7S8 against HOCl-oxLDL might
be important to further define antigenic epitope(s).
An athero-protective role of anti-oxLDL antibodies was
demonstrated in studies in which treatment with different PC-
specific related molecules reduced atherosclerotic plaque develop-
ment. First, passive immunization with PC-specific T15 IgM
antibodies reduced vein graft atherosclerosis in ApoE2/2 mice [5].
Secondly, immunization with streptococcus pneumonia vaccine,
which contain the PC-epitope is associated with an increase in PC-
specific antibodies and reduced atherosclerosis [10]. Also, immu-
nization of ApoE2/2 mice with PC linked to a carrier protein
resulted in inhibition of atherosclerosis [38]. This latter approach
resulted in the generation of both PC-specific IgM as IgG
antibodies and it was suggested that these antibodies facilitates the
removal of oxLDL from the arterial extracellular tissue (‘‘reverse
cholesterol transport’’) [38].
Interestingly, our control IgM reduced the plaque volume at the
aortic root, although this difference did not reach significance.
These findings are in accordance with Cesena et al. [39], who
showed that polyclonal IgM reduces atherosclerosis in apoE2/2
mice. Immunoglobulin therapy is known to have multiple effects
on immune function, including enhancing the auto-antibody
repertoire and down-modulating T cell function. Indeed, we could
confirm raised auto-antibodies in the control IgM group compared
to the PBS group. Even though our control monoclonal antibody
did not show reactivity against oxLDL as tested by ELISA, the
increase of antibodies to oxLDL and decrease of serum cholesterol
levels after treatment with our control monoclonal antibody makes
the results obtained by our control antibody difficult to interpret.
In our study, we observed a 20% decrease in cholesterol levels
in Moab A7S8 treated mice. Decreased cholesterol levels
contributed probably to the decreased atherosclerotic plaque
development caused by passive immunization with Moab A7S8.
We postulate that large amounts of IgM antibodies formed
immune complexes with (minimally) oxLDL in plasma and
resulted in enhanced clearance of oxLDL. During Moab A7S8
treatment IgM-ApoB immune complexes were strongly induced in
our mice. In the pneumococcal vaccination study lower cholesterol
levels were also found in the vaccinated mice in comparison with
the PBS treated mice [10]. In the study by Fario-Neto, however,
while using T15 monoclonal antibodies no decreased levels of
circulating cholesterol were found [5]. Not only IgM anti-oxLDL
levels increased during the Moab A7S8 therapy as result of passive
immunization but interestingly also specific anti-oxLDL IgG levels
increased indicating an immune modulatory phenomenon. When
IgM is injected it may bind to oxLDL in the circulation, resulting
in immune complex formation. These immune complexes could,
subsequently, be taken up by antigen presenting cells (APCs).
Figure 7. Cu-anti-oxLDL IgM titers, T15/EO6 IgM antibodies and IgM-apoB immune complexes. A. Anti-Cu-oxLDL IgM titers, B. T15/EO6
IgM antibodies and C. IgM-apoB immune complexes expressed as IgM/apoB. Mice treated with PBS (&), control IgM treated mice (o) and in mice
treated with Moab A7S8 (%).
doi:10.1371/journal.pone.0068039.g007
Anti-HOCl-oxLDL Antibody Reduces Atherosclerosis
PLOS ONE | www.plosone.org 9 July 2013 | Volume 8 | Issue 7 | e68039
Figure 8. Anti-HOCl, MDA and Cu-oxLDL IgG titers. A. Anti-HOCl-oxLDL IgG titers, B. anti-MDA-oxLDL IgG titers and C. anti-Cu-oxLDL IgG titers
in mice treated with PBS (&), control IgM treated mice (o) and in mice treated with Moab A7S8 (%).
doi:10.1371/journal.pone.0068039.g008
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These APCs present the oxLDL antigen to antigen specific
Thelper cells which could subsequently result in specific B cell
activation resulting in an increased anti-oxLDL IgG production.
Presentation of PC-specific motifs by APCs has been shown to to
be important in the generation of athroprotective effects.
Vaccination with ox-LDL reduces plaque development during
atherogenesis [40] and, importantly, ox-LDL pulsed dendritic cell
vaccinations resulted in 87% reduction in carotid artery lesion size
in the same atherosclerosis model that was used in the current
study. In a study by Ehrenstein et al. [41], it was shown that
natural IgM antibodies could play a role in facilitating an
acceleration of the primary immune response. Immune complexes
consisting of natural IgM antibodies may activate complement and
consequently may cause effective B cell activation. Indeed, it has
been demonstrated that the primary immune response can be
accelerated by the administration of specific IgM antibody.
Unfortunately, in the study of Faria-Neto et al. [5] anti-oxLDL
antibody levels in mice treated with natural T15 IgM antibodies
were not measured. Whether administration of (natural) IgM
antibodies and subsequently induction of IgM and IgG oxLDL
specific titers directly causes reduced carotid plaque development
in humans remains to be elucidated.
In conclusion, this study demonstrates an inhibition of
atherosclerotic plaque formation by an intervention with Moab
A7S8 specific for HOCl-oxLDL. Treatment resulted in decreased
cholesterol levels and induction of specific IgM and IgG titers
against oxLDL. This evidently shows the active biological
consequences of the passive immunization strategy using Moab
A7S8 in mice. Further research should be focussed on identifica-
tion of the antigenic epitope(s) on HOCl-oxLDL which could
induce these specific IgM and IgG antibody response against
oxLDL. We postulate that therapeutic effects of IgM treatment
should be further studied as a potential intervention for human
cardiovascular diseases.
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